Literature DB >> 21352991

Bleeding complications and blood product utilization with left ventricular assist device implantation.

Justin M Schaffer1, George J Arnaoutakis, Jeremiah G Allen, Eric S Weiss, Nishant D Patel, Stuart D Russell, Ashish S Shah, John V Conte.   

Abstract

BACKGROUND: Bleeding complications are a major source of morbidity and reoperation after left ventricular assist device (LVAD) implantation, yet remain poorly characterized in patients receiving LVADs. We assessed bleeding complications in an institutional cohort of LVAD patients.
METHODS: We reviewed patients who received continuous-flow (CF) LVADs at our institution (October 2004 to May 2009). Intraoperative and postoperative transfusion requirements (packed red blood cells, fresh frozen plasma, and platelets), chest tube output, and reoperation for bleeding complications were assessed. Univariate and multivariable Cox proportional hazard analysis assessed the impact of intraoperative bleeding on mortality. A subset of our patient population underwent delayed sternal closure as opposed to primary closure and an analysis of reoperation for bleeding was undertaken stratifying patients by approach to closure.
RESULTS: Eighty-six CF LVADs were implanted over our study period. Patients had poor preoperative cardiac function and high preoperative risk indices. Patients receiving LVADs had high intraoperative (11.6 ± 7.5 units) and postoperative (15.6 [±12.6] units in the first week) blood product requirements, as well as significant chest tube output (5,880 [±4,480] milliliters in the first week). On multivariable analysis, intraoperative packed red blood cell transfusions were a significant predictor of mortality. Eleven (28%) patients undergoing primary sternal closure required reoperation for bleeding, while delayed sternal closure patients generally had resolution of bleeding prior to sternal closure. The incidence of gastrointestinal bleeding was 28% at one year.
CONCLUSIONS: On multivariable analysis, intraoperative packed red blood cell transfusions were a significant predictor of 30-day and one-year mortality, while chest tube output during the first postoperative 48 hours predicted 30-day but not one-year mortality.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21352991     DOI: 10.1016/j.athoracsur.2010.11.007

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  23 in total

1.  Use of adenosine diphosphate receptor inhibitor prior to left ventricular assist device implantation is not associated with increased bleeding.

Authors:  Anjan Tibrewala; Michael E Nassif; Adam Andruska; Jerrica E Shuster; Eric Novak; Justin M Vader; Gregory A Ewald; Shane J LaRue; Scott Silvestry; Akinobu Itoh
Journal:  J Artif Organs       Date:  2016-11-09       Impact factor: 1.731

2.  Preoperative liver dysfunction influences blood product administration and alterations in circulating haemostatic markers following ventricular assist device implantation.

Authors:  Joshua R Woolley; Robert L Kormos; Jeffrey J Teuteberg; Christian A Bermudez; Jay K Bhama; Kathleen L Lockard; Nicole M Kunz; William R Wagner
Journal:  Eur J Cardiothorac Surg       Date:  2014-05-07       Impact factor: 4.191

3.  Platelet glycoprotein Ibα ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices.

Authors:  Jingping Hu; Nandan K Mondal; Erik N Sorensen; Ling Cai; Hong-Bin Fang; Bartley P Griffith; Zhongjun J Wu
Journal:  J Heart Lung Transplant       Date:  2013-09-19       Impact factor: 10.247

4.  Evaluation of GI bleeding after implantation of left ventricular assist device.

Authors:  Vladimir M Kushnir; Shivak Sharma; Gregory A Ewald; Jonathan Seccombe; Eric Novak; I-Wen Wang; Susan M Joseph; C Prakash Gyawali
Journal:  Gastrointest Endosc       Date:  2012-02-15       Impact factor: 9.427

5.  Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management.

Authors:  F W G Leebeek; R Muslem
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Ventricular assist devices and increased blood product utilization for cardiac transplantation.

Authors:  Matthew L Stone; Damien J LaPar; Ehsan Benrashid; David C Scalzo; Gorav Ailawadi; Irving L Kron; James D Bergin; Randal S Blank; John A Kern
Journal:  J Card Surg       Date:  2014-12-21       Impact factor: 1.620

7.  Hemorrhage and thrombosis with different LVAD technologies: a matter of flow?

Authors:  Vincenzo Tarzia; Edward Buratto; Giacomo Bortolussi; Michele Gallo; Jonida Bejko; Roberto Bianco; Tomaso Bottio; Gino Gerosa
Journal:  Ann Cardiothorac Surg       Date:  2014-11

8.  Hydrodynamic Impact on Blood: From Left Ventricular Assist Devices to Artificial Hearts.

Authors:  Angelo Nascimbene; Jing-Fei Dong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-03-03       Impact factor: 8.311

Review 9.  Mechanical blood trauma in assisted circulation: sublethal RBC damage preceding hemolysis.

Authors:  Salim E Olia; Timothy M Maul; James F Antaki; Marina V Kameneva
Journal:  Int J Artif Organs       Date:  2016-03-30       Impact factor: 1.595

10.  The Use of Factor Eight Inhibitor Bypass Activity (FEIBA) for the Treatment of Perioperative Hemorrhage in Left Ventricular Assist Device Implantation.

Authors:  Christian O'Donnell; Alexander J Rodriguez; Jai Madhok; Husham Sharifi; Hanjay Wang; Connor G O'Brien; Jack Boyd; William Hiesinger; Joe Hsu; Charles C Hill
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-04-25       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.